MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide highlights from
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense® Systems for early
This article represents the viewpoint of management. Background The worldwide incidence of ovarian cancer is 12.6 per 100,000 women. In the year 2006, ovarian cancer
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be
Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
Data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, charted below, illustrates the critical importance of early cancer detection. Earlier diagnosis
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance